According to a recent LinkedIn post from Scientia Vascular, the company is highlighting a clinical case using its Aristotle COLOSSUS guidewire and Socrates 38 catheter in the treatment of a proximal M1 occlusion. The case description notes that severe calcification and vessel tortuosity limited advancement of a 0.071 aspiration catheter, prompting the physician to rely on the Socrates 38 for both access and aspiration.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post reports a first-pass TICI 3 revascularization outcome in this scenario, positioning the devices as potentially effective in complex neurovascular anatomies where standard approaches may be constrained. For investors, this type of case highlight may signal ongoing physician engagement and real-world usage of Scientia Vascular’s portfolio, which could support adoption, competitive differentiation in neurointerventional devices, and, over time, revenue growth if such performance is replicated at scale.

